Cargando…

Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease

BACKGROUND: Myxomatous mitral valve disease (MMVD), a naturally occurring heart disease, affects 10% to 15% of the canine population. Canine MMVD shares many similarities with human MMVD. Untargeted metabolomics was performed to identify changes in metabolic pathways and biomarkers with potential cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qinghong, Larouche‐Lebel, Éva, Loughran, Kerry A., Huh, Terry P., Suchodolski, Jan S., Oyama, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200728/
https://www.ncbi.nlm.nih.gov/pubmed/33890477
http://dx.doi.org/10.1161/JAHA.120.018923
_version_ 1783707668765999104
author Li, Qinghong
Larouche‐Lebel, Éva
Loughran, Kerry A.
Huh, Terry P.
Suchodolski, Jan S.
Oyama, Mark A.
author_facet Li, Qinghong
Larouche‐Lebel, Éva
Loughran, Kerry A.
Huh, Terry P.
Suchodolski, Jan S.
Oyama, Mark A.
author_sort Li, Qinghong
collection PubMed
description BACKGROUND: Myxomatous mitral valve disease (MMVD), a naturally occurring heart disease, affects 10% to 15% of the canine population. Canine MMVD shares many similarities with human MMVD. Untargeted metabolomics was performed to identify changes in metabolic pathways and biomarkers with potential clinical utilities. METHODS AND RESULTS: Serum samples from 27 healthy, 22 stage B1, 18 stage B2 preclinical MMVD dogs, and 17 MMVD dogs with a history of congestive heart failure (CHF) were analyzed. Linear regression analysis identified 173 known metabolites whose concentrations were different among the 4 groups (adjusted P<0.05), of which 40% belonged to amino acid super pathways, while 30% were lipids. More than 50% of significant metabolites were correlated with left atrial diameter but not left ventricular dimension. Acylcarnitines, tricarboxylic acid cycle intermediates, and creatine accumulated in proportion to MMVD severity. α‐Ketobutyrate and ketone bodies were increased as MMVD advanced. Nicotinamide, a key substrate of the main nicotinamide adenine dinucleotide (NAD(+)) salvage pathway, was decreased, while quinolinate of the de novo NAD(+) biosynthesis was increased in CHF dogs versus healthy dogs. 3‐Methylhistidine, marker for myofibrillar protein degradation, was higher in CHF dogs than non‐CHF dogs. Trimethylamine N‐oxide (TMAO) and TMAO–producing precursors, including carnitine, phosphatidylcholine, betaine, and trimethyllysine, were increased in CHF dogs versus non‐CHF dogs. Elevated levels of uremic toxins, including guanidino compounds, TMAO, and urea, were observed in CHF dogs. Pathway analysis highlighted the importance of bioenergetics and amino acid metabolism in canine MMVD. CONCLUSIONS: Our study revealed altered energy metabolism, amino acid metabolic programming, and reduced renal function in the development of MMVD and CHF. Complex interplays along the heart‐kidney‐gut axis were implicated.
format Online
Article
Text
id pubmed-8200728
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82007282021-06-15 Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease Li, Qinghong Larouche‐Lebel, Éva Loughran, Kerry A. Huh, Terry P. Suchodolski, Jan S. Oyama, Mark A. J Am Heart Assoc Original Research BACKGROUND: Myxomatous mitral valve disease (MMVD), a naturally occurring heart disease, affects 10% to 15% of the canine population. Canine MMVD shares many similarities with human MMVD. Untargeted metabolomics was performed to identify changes in metabolic pathways and biomarkers with potential clinical utilities. METHODS AND RESULTS: Serum samples from 27 healthy, 22 stage B1, 18 stage B2 preclinical MMVD dogs, and 17 MMVD dogs with a history of congestive heart failure (CHF) were analyzed. Linear regression analysis identified 173 known metabolites whose concentrations were different among the 4 groups (adjusted P<0.05), of which 40% belonged to amino acid super pathways, while 30% were lipids. More than 50% of significant metabolites were correlated with left atrial diameter but not left ventricular dimension. Acylcarnitines, tricarboxylic acid cycle intermediates, and creatine accumulated in proportion to MMVD severity. α‐Ketobutyrate and ketone bodies were increased as MMVD advanced. Nicotinamide, a key substrate of the main nicotinamide adenine dinucleotide (NAD(+)) salvage pathway, was decreased, while quinolinate of the de novo NAD(+) biosynthesis was increased in CHF dogs versus healthy dogs. 3‐Methylhistidine, marker for myofibrillar protein degradation, was higher in CHF dogs than non‐CHF dogs. Trimethylamine N‐oxide (TMAO) and TMAO–producing precursors, including carnitine, phosphatidylcholine, betaine, and trimethyllysine, were increased in CHF dogs versus non‐CHF dogs. Elevated levels of uremic toxins, including guanidino compounds, TMAO, and urea, were observed in CHF dogs. Pathway analysis highlighted the importance of bioenergetics and amino acid metabolism in canine MMVD. CONCLUSIONS: Our study revealed altered energy metabolism, amino acid metabolic programming, and reduced renal function in the development of MMVD and CHF. Complex interplays along the heart‐kidney‐gut axis were implicated. John Wiley and Sons Inc. 2021-04-23 /pmc/articles/PMC8200728/ /pubmed/33890477 http://dx.doi.org/10.1161/JAHA.120.018923 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Li, Qinghong
Larouche‐Lebel, Éva
Loughran, Kerry A.
Huh, Terry P.
Suchodolski, Jan S.
Oyama, Mark A.
Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
title Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
title_full Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
title_fullStr Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
title_full_unstemmed Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
title_short Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
title_sort metabolomics analysis reveals deranged energy metabolism and amino acid metabolic reprogramming in dogs with myxomatous mitral valve disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200728/
https://www.ncbi.nlm.nih.gov/pubmed/33890477
http://dx.doi.org/10.1161/JAHA.120.018923
work_keys_str_mv AT liqinghong metabolomicsanalysisrevealsderangedenergymetabolismandaminoacidmetabolicreprogrammingindogswithmyxomatousmitralvalvedisease
AT larouchelebeleva metabolomicsanalysisrevealsderangedenergymetabolismandaminoacidmetabolicreprogrammingindogswithmyxomatousmitralvalvedisease
AT loughrankerrya metabolomicsanalysisrevealsderangedenergymetabolismandaminoacidmetabolicreprogrammingindogswithmyxomatousmitralvalvedisease
AT huhterryp metabolomicsanalysisrevealsderangedenergymetabolismandaminoacidmetabolicreprogrammingindogswithmyxomatousmitralvalvedisease
AT suchodolskijans metabolomicsanalysisrevealsderangedenergymetabolismandaminoacidmetabolicreprogrammingindogswithmyxomatousmitralvalvedisease
AT oyamamarka metabolomicsanalysisrevealsderangedenergymetabolismandaminoacidmetabolicreprogrammingindogswithmyxomatousmitralvalvedisease